Athersys Sees Efficacy Sign In MultiStem Phase I Safety Study In Heart Attack
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Heart attack patients treated with Athersys' adult stem cell product MultiStem during a Phase I safety study showed improvement in cardiac function, a surprise early efficacy signal that has the company headed into Phase II studies with a spring in its step